Premature Loss of Permanent Teeth in Allgrove (4A) Syndrome in Two Related Families

Total Page:16

File Type:pdf, Size:1020Kb

Premature Loss of Permanent Teeth in Allgrove (4A) Syndrome in Two Related Families Iran J Pediatr Case Report Mar 2010; Vol 20 (No 1), Pp:101-106 Premature Loss of Permanent Teeth in Allgrove (4A) Syndrome in Two Related Families Zahra Razavi*1, MD; Mohammad­Mehdi Taghdiri¹, MD; Fatemeh Eghbalian¹, MD; Nooshin Bazzazi², MD 1. Department of Pediatrics, Hamadan University of Medical Sciences, IR Iran 2. Department of Ophthalmology, Hamadan University of Medical Sciences, IR Iran Received: Feb 07, 2009; Final Revision: Apr 27, 2009; Accepted: May 06, 2009 Abstract Background: Allgrove syndrome is a rare autosomal recessive condition characterized by adrenal insufficiency, achalasia, alacrima and occasionally autonomic disturbances. Mutations in the AAAS gene, on chromosome 12q13 have been implicated as a cause of this disorder. Case(s) Presentation: We present various manifestations of this syndrome in two related families each with two affected siblings in which several members had symptoms including reduced tear production, mild developmental delay, achalasia, neurological disturbances and also premature loss of permanent teeth in two of them, Conclusion: The importance of this report is dental involvement (loss of permanent teeth) in Allgrove syndrome that has not been reported in literature. Iranian Journal of Pediatrics, Volume 20 (Number 1), March 2010, Pages: 101­106 Key Words: Achalasia, Adrenocortical Insufficiency, Alacrimia (Allgrove, triple‐A) Protein, Human; AAAS Protein, Human; Teeth; Allgrove Syndrome; Triple A Syndrome Protein, Human Introduction autonomic disturbances associated with Allgrove syndrome leading one author to In 1978 Allgrove and colleagues described 2 recommend the name 4A syndrome (adreno‐ unrelated pairs of siblings with achalasia and cortical insufficiency, achalasia of cardia, ACTH insensivity, three had impaired alacrima and autonomic abnormalities)[2‐4]. lacrimation and one also had autonomic There is significant variability in the clinical dysfunction. This triad (achalasia, adrenal presentation [5]. insufficiency and alacrima) became known as Additional features included hyper‐reflexia, Ttriple A Syndrome [1]. muscle weakness and nasal speech. Incidence is During the following years several reports in the unknown and only few numbers of families and literature have focused on more global case reports exist in literature. Inheritance is * Corresponding Author; Address: Be’ssat Hospital, Hamadan, IR Iran E-mail: [email protected] © 2010 by Pediatrics Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, All rights reserved. 102 Allgrove Syndrome in 2 Related Families; Z Razavi, et al autosomal recessive and most patients have poor school performance and learning consanguineous parents [6], but autosomal difficulties. There was loosening of permanent dominant forms with incomplete penetrance teeth when she was l0 years old, and became have also been reported [7,8]. Parental near totally edentulous by the age of 13 years. consanguinity and previously affected siblings She was also suffering from muscular wasting are the primary risk factors. and weakness. Her sister had achalasia and Mutations in the AAAS gene, which encodes hearing deficits. the product aladin, on chromosome 12q13 have On physical examination she was found to be been implicated as a cause of this disorder. This of short stature and delayed in response. Blood gene belongs to WD‐repeat regulatory protein pressure was normal without orthostatic family which exhibits wide functional diversity. hypotension, weight 25 kg (Z score ‐3 SD), height The encoded protein, aladin, may help regulate 132 cm (Z score ‐4 SD) according to NCHS nucleo‐cytoplasmic transport of other proteins. growth chart. Pubertal stage: breast SMR (sex High expression of this protein is seen in the maturity rating) 1 and pubic hair SMR 2 adrenal gland, brain and gastrointestinal tract, according to Tanner's staging system. the organs in which the main pathologic She had a distinct facial appearance consisting manifestations of disease occur[9‐14]. Some of narrow upper lip and down–turned mouth authors believed that the pathology of this with nasal speech. The patient was near totally condition may be due to a progressive loss of edentulous. There was distal wasting in the cholinergic function throughout the body [8,15]. arms, lower limb, and significant weakness of Age at onset of symptoms is variable but the legs. patients usually present during the first decade Her past hospital records ‐ before treatment of life with hypoglycemia, adrenal crisis or with prednisolone– showed normal thyroid dysphagia. Achalasia or alacrima may precede function tests and routine biochemical and adrenal insufficiency. Adult patients with 4A hematological tests. Serum glucose was low (30 syndrome may present with multisystem mg/dL). Serum cortisol was 1.5 µg/dL (normal neurological disease [4]. range 5‐20) before, 3 µg/dL 30 minutes and 2 This article reports two pairs of siblings in µg/dL 4 hours after intramuscular injection of two related families with broad clinical features 250 µg long acting ACTH. (Normal response: of the syndrome with particular attention to peak plasma cortisol level greater than 19 premature loss of permanent teeth in two µg/dL). siblings. Ophthalmologic evaluation and Schirmer test revealed alacrima. Barium esophago‐gram did not demonstrate achalasia. The clinical finding was typical for Allgrove syndrome. Case(s) Presentation Case 2: This 15‐year‐old girl was second sibling Family 1 of case 1 who was born of consanguineous Case 1: A 13 year‐old girl with unremarkable parents. She first presented with vomiting and birth history was referred to our endocrinology difficulty in swallowing at age 5 and clinic for further follow up. She was diagnosed subsequently underwent esophageal dilatations with familial gluococorticoid insufficiency at age for achalasia. 4 after a hypoglycemic seizure with low cortisol She lost her teeth prematurely one by one at and elevated ACTH level and was discharged on age 13. She also was noted to have learning oral prednisolone. Her parents were cousins and difficulties, poor school performance and she was born at term. hearing deficit. Review of systems was positive for crying On examination she was mentally disabled without tears from early infancy and darkening and had dysmorphic facial features with nasal of skin at age 4. By age 7 she was felt to have speech. She was partially edentulous. Blood Iran J Pediatr, Vol 20 (No 1); Mar 2010 103 pressure, weight and height were normal. Breast Based on these findings, Allgrove syndrome and pubic hair were in SMR 2. Additional diagnosis was established. findings were muscular wasting, weakness and alacrima. Case 4: This 10‐year‐old patient is older sister Bilateral hearing loss was confirmed by of case 3 and was born with unremarkable birth hearing evaluation. Routine biochemical, history. She was evaluated because of reduced hematological and serum cortisol level before tear production and positive history of Allgrove and after ACTH stimulation test were normal. syndrome in her brother. At age 2 she was noted Neither of the two patients had significant to have prominent neuro‐developmental delay dental caries or periodontal disease, we did not (delay in sitting, walking and speech). She had find abnormal results in clinical and laboratory not attended school normally because of investigations for their teeth loss. learning difficulties. Achalasia and alacrima were valuable clues to On examination she was normal for weight, speculate that she had Allgrove syndrome. height and blood pressure without orthostatic changes. Clinical findings included distinct facial Family 2 appearance characteristic of Allgrove syndrome, Case 3: A 6‐year old boy born to consanguineous nasal voice, dysarthria, mental retardation, parents (cousin to cases 1 and 2) was referred to ataxia (tandem gait and finger‐to‐nose testing our clinic with darkening of skin, developmental was disturbed). Slit lamp examination and delay and photophobia. Hyperpigmentation over ophtalmoscopy were normal, but Schirmer's test the knuckles of the hands and feet had typically showed alacrima. Barium developed gradually over the last 12 months. esophagogram did not show dilated esophagus. The patient's past medical history was Biochemical, hormonal and hematological significant for esophageal surgery and screening were negative except for low cortisol cardiomyotomy for achalasia manifested by and blood sugar and high ACTH (serum glucose recurrent vomiting. 40 mg/dL, serum cortisol 3.4 µg/dL, 4 µg/dL, On physical examination long thin face with and 2.4 µg/dL, immediately before, 30 minutes long philtrum, narrow upper lip characteristic of and 4 hours after intramuscular injection of 250 Allgrove syndrome was observed. He was µg long acting ACTH, respectively). ACTH level mentally disabled. The weight was 16.5 kg (Z was 60 pg/ml. In the light of these findings a score ‐2.5 standard deviation) and the height diagnosis of Allgrove syndrome was considered. was 103 cm (Z score ‐3 standard deviation). Clinical findings in patients are summarized in Neurologic findings consisted of dysarthria, and table 1. mild gait disturbance. Heart rate was 90/min and blood pressure 100/60 mmHg in supine position, but he had marked postural fall in both. (60/min and 70/40 in upright position, respectively). Schirmer's test revealed right eye Discussion 4 mm and left eye 2 mm of wetting (alacrima was confirmed). When adrenal insufficiency is seen in Serum Na, K, aldosterone, renin,
Recommended publications
  • Peripheral Neuropathy in Complex Inherited Diseases: an Approach To
    PERIPHERAL NEUROPATHY IN COMPLEX INHERITED DISEASES: AN APPROACH TO DIAGNOSIS Rossor AM1*, Carr AS1*, Devine H1, Chandrashekar H2, Pelayo-Negro AL1, Pareyson D3, Shy ME4, Scherer SS5, Reilly MM1. 1. MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, WC1N 3BG, UK. 2. Lysholm Department of Neuroradiology, National Hospital for Neurology and Neurosurgery, London, WC1N 3BG, UK. 3. Unit of Neurological Rare Diseases of Adulthood, Carlo Besta Neurological Institute IRCCS Foundation, Milan, Italy. 4. Department of Neurology, University of Iowa, 200 Hawkins Drive, Iowa City, IA 52242, USA 5. Department of Neurology, University of Pennsylvania, Philadelphia, PA 19014, USA. * These authors contributed equally to this work Corresponding author: Mary M Reilly Address: MRC Centre for Neuromuscular Diseases, 8-11 Queen Square, London, WC1N 3BG, UK. Email: [email protected] Telephone: 0044 (0) 203 456 7890 Word count: 4825 ABSTRACT Peripheral neuropathy is a common finding in patients with complex inherited neurological diseases and may be subclinical or a major component of the phenotype. This review aims to provide a clinical approach to the diagnosis of this complex group of patients by addressing key questions including the predominant neurological syndrome associated with the neuropathy e.g. spasticity, the type of neuropathy, and the other neurological and non- neurological features of the syndrome. Priority is given to the diagnosis of treatable conditions. Using this approach, we associated neuropathy with one of three major syndromic categories - 1) ataxia, 2) spasticity, and 3) global neurodevelopmental impairment. Syndromes that do not fall easily into one of these three categories can be grouped according to the predominant system involved in addition to the neuropathy e.g.
    [Show full text]
  • Prevalence and Incidence of Rare Diseases: Bibliographic Data
    Number 1 | January 2019 Prevalence and incidence of rare diseases: Bibliographic data Prevalence, incidence or number of published cases listed by diseases (in alphabetical order) www.orpha.net www.orphadata.org If a range of national data is available, the average is Methodology calculated to estimate the worldwide or European prevalence or incidence. When a range of data sources is available, the most Orphanet carries out a systematic survey of literature in recent data source that meets a certain number of quality order to estimate the prevalence and incidence of rare criteria is favoured (registries, meta-analyses, diseases. This study aims to collect new data regarding population-based studies, large cohorts studies). point prevalence, birth prevalence and incidence, and to update already published data according to new For congenital diseases, the prevalence is estimated, so scientific studies or other available data. that: Prevalence = birth prevalence x (patient life This data is presented in the following reports published expectancy/general population life expectancy). biannually: When only incidence data is documented, the prevalence is estimated when possible, so that : • Prevalence, incidence or number of published cases listed by diseases (in alphabetical order); Prevalence = incidence x disease mean duration. • Diseases listed by decreasing prevalence, incidence When neither prevalence nor incidence data is available, or number of published cases; which is the case for very rare diseases, the number of cases or families documented in the medical literature is Data collection provided. A number of different sources are used : Limitations of the study • Registries (RARECARE, EUROCAT, etc) ; The prevalence and incidence data presented in this report are only estimations and cannot be considered to • National/international health institutes and agencies be absolutely correct.
    [Show full text]
  • French Clinical Practice Guidelines for Moyamoya Angiopathy
    NEUROL-1879; No. of Pages 12 r e v u e n e u r o l o g i q u e x x x ( 2 0 1 8 ) x x x – x x x Available online at ScienceDirect www.sciencedirect.com Practice guidelines French clinical practice guidelines for Moyamoya angiopathy a, b c,1 d,1 D. Herve´ *, M. Kossorotoff , D. Bresson , T. Blauwblomme , e,1 f g h i M. Carneiro , E. Touze , F. Proust , I. Desguerre , S. Alamowitch , j k l m n J.-P. Bleton , A. Borsali , E. Brissaud , F. Brunelle , L. Calviere , o p q r M. Chevignard , G. Geffroy-Greco , S. Faesch , M.-O. Habert , s t a u v H. De Larocque , P. Meyer , S. Reyes , L. Thines , E. Tournier-Lasserve , a H. Chabriat a De´partement de neurologie, centre de re´fe´rence des maladies vasculaires rares du cerveau et de l’œil (CERVCO), groupe hospitalier Saint-Louis-Lariboisie`re-Fernand-Widal, 2, rue Ambroise-Pare´, 75010 Paris, France b Centre national de re´fe´rence de l’AVC de l’enfant, hoˆpital universitaire Necker-Enfants malades, AP–HP, 149, rue de Se`vres, 75015 Paris, France c Service de neurochirurgie, groupe hospitalier Saint-Louis-Lariboisie`re-Fernand-Widal, 2, rue Ambroise-Pare´, 75010 Paris, France d Service de neurochirurgie pe´diatrique, hoˆpital universitaire Necker–Enfants-Malades, AP–HP, 149, rue de Se`vres, 75015 Paris, France e Neurologie pe´diatrique, hoˆpital Femme-Me`re-Enfant, hospices Civils-de-Lyon, 59, boulevard Pinel, 69677 Bron, France f Service de neurologie, Normandie universite´, Unicaen, Inserm U1237, CHU Caen-Normandie, avenue de la Coˆte-de- Nacre, 14033 Caen, France g Service de neurochirurgie,
    [Show full text]
  • Current Affairs Q&A
    Current Affairs Q&A PDF This is Paid PDF provided by AffairsCloud.com, Our team is working hard in back end to provide quality PDF. If you not buy this paid PDF subscription plan, we kindly request you to buy pdf to avail this service. Help Us To Grow & Provide Quality Service Subscribe(Buy) Current Affairs PDF 2019 - Pocket, Study and Q&A (English & Hindi) Current Affairs Q&A PDF - September 2019 Table of Contents INDIAN AFFAIRS ................................................................................................................................................................................... 2 INTERNATIONAL AFFAIRS ............................................................................................................................................................ 59 BANKING & FINANCE ....................................................................................................................................................................... 87 ECONOMY & BUSINESS ................................................................................................................................................................. 112 AWARDS & RECOGNITIONS ........................................................................................................................................................ 128 APPOINTMENTS & RESIGNS ....................................................................................................................................................... 154 SCIENCE & TECHNOLOGY ...........................................................................................................................................................
    [Show full text]
  • Orphanet Report Series Rare Diseases Collection
    Marche des Maladies Rares – Alliance Maladies Rares Orphanet Report Series Rare Diseases collection DecemberOctober 2013 2009 List of rare diseases and synonyms Listed in alphabetical order www.orpha.net 20102206 Rare diseases listed in alphabetical order ORPHA ORPHA ORPHA Disease name Disease name Disease name Number Number Number 289157 1-alpha-hydroxylase deficiency 309127 3-hydroxyacyl-CoA dehydrogenase 228384 5q14.3 microdeletion syndrome deficiency 293948 1p21.3 microdeletion syndrome 314655 5q31.3 microdeletion syndrome 939 3-hydroxyisobutyric aciduria 1606 1p36 deletion syndrome 228415 5q35 microduplication syndrome 2616 3M syndrome 250989 1q21.1 microdeletion syndrome 96125 6p subtelomeric deletion syndrome 2616 3-M syndrome 250994 1q21.1 microduplication syndrome 251046 6p22 microdeletion syndrome 293843 3MC syndrome 250999 1q41q42 microdeletion syndrome 96125 6p25 microdeletion syndrome 6 3-methylcrotonylglycinuria 250999 1q41-q42 microdeletion syndrome 99135 6-phosphogluconate dehydrogenase 67046 3-methylglutaconic aciduria type 1 deficiency 238769 1q44 microdeletion syndrome 111 3-methylglutaconic aciduria type 2 13 6-pyruvoyl-tetrahydropterin synthase 976 2,8 dihydroxyadenine urolithiasis deficiency 67047 3-methylglutaconic aciduria type 3 869 2A syndrome 75857 6q terminal deletion 67048 3-methylglutaconic aciduria type 4 79154 2-aminoadipic 2-oxoadipic aciduria 171829 6q16 deletion syndrome 66634 3-methylglutaconic aciduria type 5 19 2-hydroxyglutaric acidemia 251056 6q25 microdeletion syndrome 352328 3-methylglutaconic
    [Show full text]
  • Albany Med Conditions and Treatments
    Albany Med Conditions Revised 3/28/2018 and Treatments - Pediatric Pediatric Allergy and Immunology Conditions Treated Services Offered Visit Web Page Allergic rhinitis Allergen immunotherapy Anaphylaxis Bee sting testing Asthma Drug allergy testing Bee/venom sensitivity Drug desensitization Chronic sinusitis Environmental allergen skin testing Contact dermatitis Exhaled nitric oxide measurement Drug allergies Food skin testing Eczema Immunoglobulin therapy management Eosinophilic esophagitis Latex skin testing Food allergies Local anesthetic skin testing Non-HIV immune deficiency disorders Nasal endoscopy Urticaria/angioedema Newborn immune screening evaluation Oral food and drug challenges Other specialty drug testing Patch testing Penicillin skin testing Pulmonary function testing Pediatric Bariatric Surgery Conditions Treated Services Offered Visit Web Page Diabetes Gastric restrictive procedures Heart disease risk Laparoscopic surgery Hypertension Malabsorptive procedures Restrictions in physical activities, such as walking Open surgery Sleep apnea Pre-assesment Pediatric Cardiothoracic Surgery Conditions Treated Services Offered Visit Web Page Aortic valve stenosis Atrial septal defect repair Atrial septal defect (ASD Cardiac catheterization Cardiomyopathies Coarctation of the aorta repair Coarctation of the aorta Congenital heart surgery Congenital obstructed vessels and valves Fetal echocardiography Fetal dysrhythmias Hypoplastic left heart repair Patent ductus arteriosus Patent ductus arteriosus ligation Pulmonary artery stenosis
    [Show full text]
  • Management of Stroke in Neonates and Children: a Scientific Statement from the American Heart Association/American Stroke Association
    UCSF UC San Francisco Previously Published Works Title Management of Stroke in Neonates and Children: A Scientific Statement From the American Heart Association/American Stroke Association. Permalink https://escholarship.org/uc/item/0sw5j7c1 Journal Stroke, 50(3) ISSN 0039-2499 Authors Ferriero, Donna M Fullerton, Heather J Bernard, Timothy J et al. Publication Date 2019-03-01 DOI 10.1161/str.0000000000000183 Peer reviewed eScholarship.org Powered by the California Digital Library University of California AHA/ASA Scientific Statement Management of Stroke in Neonates and Children A Scientific Statement From the American Heart Association/American Stroke Association The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Donna M. Ferriero, MD, MS, FAHA, Co-Chair; Heather J. Fullerton, MD, MAS, Co-Chair; Timothy J. Bernard, MD, MSCS; Lori Billinghurst, MD, MSc, FRCPC; Stephen R. Daniels, MD, PhD; Michael R. DeBaun, MD, MPH; Gabrielle deVeber, MD; Rebecca N. Ichord, MD; Lori C. Jordan, MD, PhD, FAHA; Patricia Massicotte, MSc, MD, MHSc; Jennifer Meldau, MSN; E. Steve Roach, MD, FAHA; Edward R. Smith, MD; on behalf of the American Heart Association Stroke Council and Council on Cardiovascular and Stroke Nursing Purpose—Much has transpired since the last scientific statement on pediatric stroke was published 10 years ago. Although stroke has long been recognized as an adult health problem causing substantial morbidity and mortality, it is also an important cause of acquired brain injury in young patients, occurring most commonly in the neonate and throughout childhood. This scientific statement represents a synthesis of data and a consensus of the leading experts in childhood cardiovascular disease and stroke.
    [Show full text]
  • With a Learning Disability; Guidance for General Practice
    Improving identification of people with a learning disability: guidance for general practice NHS England and Improvement Publishing Approval Reference: 001030 Version 1 NHS England and NHS Improvement Contents Introduction .................................................................................... 2 Actions for practices ....................................................................... 4 Appendix 1: List of codes that indicate a learning disability ........... 7 Appendix 2: List of codes that may indicate a learning disability . 14 Appendix 3: List of outdated codes .............................................. 20 Appendix 4: Learning disability identification check-list ............... 22 1 | Contents Introduction 1. The NHS Long Term Plan1 commits to improve uptake of the existing annual health check in primary care for people aged over 14 years with a learning disability, so that at least 75% of those eligible have a learning disability health check each year. 2. There is also a need to increase the number of people receiving the annual seasonal flu vaccination, given the level of avoidable mortality associated with respiratory problems. 3. In 2017/18, only 44.6% of patients with a learning disability received a flu vaccination and only 55.1% of patients with a learning disability received an annual learning disability health check.2 4. In June 2019, NHS England and NHS Improvement announced a series of measures to improve coverage of annual health checks and flu vaccination for people with a learning disability. One of the commitments was to improve the quality of registers for people with a learning disability3. Clinical coding review 5. Most GP practices have developed a register of their patients known to have a learning disability. This has been developed from clinical diagnoses, from information gathered from learning disabilities teams and social services and has formed the basis of registers for people with learning disability developed for the Quality and Outcomes Framework (QOF).
    [Show full text]
  • Familial Achalasia, a Case Report
    Iran J Pediatr Case Report Jun 2010; Vol 20 (No 2), Pp:233-236 Familial Achalasia, a Case Report Farzaneh Motamed1,2, MD; Vajiheh Modaresi*2, MD, and Kambiz Eftekhari2, MD 1. Department of Pediatrics, Tehran University of Medical Sciences, Tehran, IR Iran 2. Children's Medical Center, Pediatric Center of Excellence, Tehran, IR Iran Received: May 03, 2009; Final Revision: Sep 24, 2009; Accepted: Nov 05, 2009 Abstract Background: Although achalasia is a relatively rare disease in pediatric age group, it must be considered for differential diagnosis of esophageal disorders in children with positive family history even in the absence of typical clinical manifestations. Case Presentation: A 5‐month old boy was hospitalized for cough and mild respiratory distress. Because of positive history of achalasia in his mother, achalasia was detected in esophgagography. Pneumatic dilation through endoscopy was successful. A 12‐month follow‐ up revealed no problem. Conclusion: Achalasia must be considered for differential diagnosis in children with positive family history of achalasia even in the absence of typical clinical manifestations. An autosomal recessive mode of inheritance is probable. We suggest further researches and genetic studies to establish the pattern of inheritance. Iranian Journal of Pediatrics, Volume 20 (Number 2), June 2010, Pages: 233­236 Key Words: Achalasia, Familial; Esophageal dysmotility; Dysphagia; Peristalsis Introduction children per year in UK[2]. Most associations are seen among siblings or in monozygotic twins. One of the causes of dysphagia due to more Parent‐child association is even rarer[1]. distal primary esophageal dysmotility is Degenerative, autoimmune and infectious achalasia with unknown etiology characterized factors are possible etiologies.
    [Show full text]
  • Esophageal Multichannel Intraluminal Impedance and Ph
    MAEDICA – a Journal of Clinical Medicine 2014; 9(4): 391-394 Mædica - a Journal of Clinical Medicine CAASESE RREPORTEPORT Esophageal Multichannel Intraluminal Impedance and pH Monitoring in the Evaluation of Achalasia and Gastroesophageal Reflux Disease in a Child with Down Syndrome: a Case Report Mihai-Mirel STOICESCUa; Mihai MOCANUb; Felicia GALOSa; Mihai MUNTEANUb; Simina VISANb; Coriolan ULMEANUa; Mihaela BALGRADEANa a”Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania b”Marie Sklodowska Curie” Emergency Children’s Hospital, Bucharest, Romania ABSTRACT We report the case of a rare association between achalasia and Down syndrome in a child present- ing with symptoms that suggest a gastroesophageal reflux. Evaluation of the patient with 24-hour multichannel intraluminal impedance and pH recording and upper endoscopy lead to the diagnosis of achalasia. However, the persistence of the symptoms after the concurrent surgical myomectomy and fundoplication has led to repeat pH-impedance monitoring testing and endoscopy, which identified the presence of gastroesophageal reflux disease. We emphasize in this paper the importance of multichannel intraluminal impedance and pH monitoring in detecting esophageal motility disorders. INTRODUCTION line reflux. Because impedance catheters have multiple sets of impedance-measuring rings, ombined multichannel intralumi- bolus movement and direction (antegrade or nal impedance and pH recording retrograde) can be assessed (1). (MII-pH) in the esophagus has Normal standards for MII-pH are not yet es- been available for more than fif- tablished in children, but it allows one to in- teen years for the study of fluid crease the accuracy of observations during Cmovement in the esophagus. It reliably detects esophageal pH-monitoring and draw relevant solid, liquid, gas and mixed liquid-gas reflux conclusions (2).
    [Show full text]
  • Cme Review Article 4
    Volume 72, Number 2 OBSTETRICAL AND GYNECOLOGICAL SURVEY Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved. CME REVIEWARTICLE 4 CHIEF EDITOR’S NOTE: This article is part of a series of continuing education activities in this Journal through which a total of 36 AMA PRA Category 1 Credits™ can be earned in 2017. Instructions for how CME credits can be earned appear on the last page of the Table of Contents. Travel During Pregnancy: Considerations for the Obstetric Provider Kathleen M. Antony, MD, MSCI,* Deborah Ehrenthal, MD, MPH,† Ann Evensen, MD,‡ and J. Igor Iruretagoyena, MD* *Assistant Professor, Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, †Associate Professor, Department of Obstetrics and Gynecology, and ‡Associate Professor, Department of Family Medicine and Community Health, University of Wisconsin–Madison, Madison, WI Importance: Travel among US citizens is becoming increasingly common, and travel during pregnancy is also speculated to be increasingly common. During pregnancy, the obstetric provider may be the first or only clinician approached with questions regarding travel. Objective: In this review, we discuss the reasons women travel during pregnancy, medical considerations for long-haul air travel, destination-specific medical complications, and precautions for pregnant women to take both before travel and while abroad. To improve the quality of pretravel counseling for patients before or during pregnancy, we have created 2 tools: a guide for assessing the pregnant patient’s risk during travel and a pretravel checklist for the obstetric provider. Evidence Acquisition: A PubMed search for English-language publications about travel during pregnancy was performed using the search terms “travel” and “pregnancy” and was limited to those published since the year 2000.
    [Show full text]
  • Prevalence of Rare Diseases: Bibliographic Data
    Prevalence distribution of rare diseases 200 180 160 140 120 100 80 Number of diseases 60 November 2009 40 May 2014 Number 1 20 0 0 5 10 15 20 25 30 35 40 45 50 Estimated prevalence (/100000) Prevalence of rare diseases: Bibliographic data Listed in alphabetical order of disease or group of diseases www.orpha.net Methodology A systematic survey of the literature is being Updated Data performed in order to provide an estimate of the New information from available data sources: EMA, prevalence of rare diseases in Europe. An updated new scientific publications, grey literature, expert report will be published regularly and will replace opinion. the previous version. This update contains new epidemiological data and modifications to existing data for which new information has been made Limitation of the study available. The exact prevalence rate of each rare disease is difficult to assess from the available data sources. Search strategy There is a low level of consistency between studies, a poor documentation of methods used, confusion The search strategy is carried out using several data between incidence and prevalence, and/or confusion sources: between incidence at birth and life-long incidence. - Websites: Orphanet, e-medicine, GeneClinics, EMA The validity of the published studies is taken for and OMIM ; granted and not assessed. It is likely that there - Registries, RARECARE is an overestimation for most diseases as the few - Medline is consulted using the search algorithm: published prevalence surveys are usually done in «Disease names» AND Epidemiology[MeSH:NoExp] regions of higher prevalence and are usually based OR Incidence[Title/abstract] OR Prevalence[Title/ on hospital data.
    [Show full text]